Remove Coronary Artery Disease Remove Stent Remove Thrombosis
article thumbnail

SMT Publishes Trial Results for Supraflex Cruz Stent

DAIC

Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).

Stent 52
article thumbnail

Abstract 4132742: Fractional flow reserve guided complete revascularization versus Culprit-only percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. A meta-analysis of randomized controlled trials

Circulation

A random-effects model was used for outcomes with high heterogeneity.Results:We included 4 RCTs with 3173 patients comparing FFR-guided CR with culprit-only PCI in patients with STEMI and multivessel coronary artery diseases. vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2%

article thumbnail

Prolocor, Slingshot Bioscience Publish Paper on Prognostic Tool to Help Assess Thrombosis Risk

DAIC

"Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronary artery disease patients, particularly after coronary stenting. The Prolocor pFCG test will be an important asset as we tailor antiplatelet therapies to balance thrombotic and bleeding risk" said Dominick J.

article thumbnail

Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention

Open Heart

We aimed to perform a systematic review and meta-analysis to study the effects of colchicine in patients with symptomatic coronary artery disease (CAD) who have undergone PCI. These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stent thrombosis.

article thumbnail

Grüntzig’s technique, relearnt

The British Journal of Cardiology

That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. It was unprecedented, going against received wisdom.

article thumbnail

Case Report: Kounis syndrome due to cryptopteran bite

Frontiers in Cardiovascular Medicine

Background Kounis syndrome is an acute coronary syndrome (ACS) caused by allergic reactions, including coronary artery spasm (type I) caused by allergies without coronary predisposing factors, pre-existing coronary atherosclerosis, and coronary artery disease.

article thumbnail

Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials

Open Heart

Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency.

Stent 52